Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Kyowa Kirin, Inc.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1949-01-01

Employees: 7.1K

Market Cap: $12B

Website: http://www.kyowa-kirin.co.jp/

Clinical Trials

Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

Phase 2

Completed

Conditions: X-Linked Hypophosphatemia

Interventions: Biological: Burosumab

First Posted Date: 2016-04-25

Last Posted Date: 2024-05-06

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 13

Registration Number: NCT02750618

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸
Shriners Hospital for Children, Saint Louis, Missouri, United States

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Hepatocellular Carcinoma
HCC
Solid Tumor
Cancer
Carcinoma

Interventions: Biological: Mogamulizumab + Nivolumab

First Posted Date: 2016-03-10

Last Posted Date: 2024-04-25

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 114

Registration Number: NCT02705105

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis
Digestive System Diseases
Colitis, Ulcerative
Colitis
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Colonic Diseases
Autoimmune Disease
Abdominal Pain

Interventions: Drug: KHK4083
Drug: Placebo

First Posted Date: 2016-01-06

Last Posted Date: 2024-04-26

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 66

Registration Number: NCT02647866

Locations: 🇷🇸
Bežanija Kosa, Belgrade, Serbia

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

Phase 3

Completed

Conditions: X-linked Hypophosphatemia

Interventions: Biological: burosumab

First Posted Date: 2015-09-01

Last Posted Date: 2024-06-18

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 14

Registration Number: NCT02537431

Locations: 🇺🇸
UCSF Medical Center at Mission, San Francisco, California, United States
🇺🇸
Yale University School of Medicine - Yale New-Haven Hospital/Yale Center for Clinical Investigation, New Haven, Connecticut, United States
🇺🇸
Indiana University Department of Medicine University Hospital, Indianapolis, Indiana, United States

and more 11 locations

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

Phase 3

Completed

Conditions: X-linked Hypophosphatemia

Interventions: Biological: burosumab
Other: Placebo

First Posted Date: 2015-08-18

Last Posted Date: 2024-06-18

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 134

Registration Number: NCT02526160

Locations: 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
University of California-San Francisco Medical Center, San Francisco, California, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 22 locations

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: mogamulizumab
Drug: Docetaxel

First Posted Date: 2015-02-09

Last Posted Date: 2018-11-30

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 13

Registration Number: NCT02358473

Locations: 🇺🇸
Horizon Oncology, Lafayette, Indiana, United States
🇺🇸
John Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States

and more 2 locations

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

Phase 2

Completed

Conditions: X-Linked Hypophosphatemia

Interventions: Biological: KRN23

First Posted Date: 2014-12-09

Last Posted Date: 2024-05-06

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 20

Registration Number: NCT02312687

Locations: 🇺🇸
University California San Francisco Hospital, San Francisco, California, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Indiana University Hospital, Indianapolis, Indiana, United States

and more 2 locations

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Phase 2

Completed

Conditions: Epidermal Nevus Syndrome (ENS)
Tumor Induced Osteomalacia (TIO)

Interventions: Biological: Burosumab

First Posted Date: 2014-12-01

Last Posted Date: 2024-05-06

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 17

Registration Number: NCT02304367

Locations: 🇺🇸
Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, Colorado, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Indiana University Hospital, Indianapolis, Indiana, United States

and more 4 locations

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Biological: mogamulizumab
Biological: tremelimumab
Biological: MEDI4736 (Durvalumab)

First Posted Date: 2014-11-25

Last Posted Date: 2024-04-25

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 64

Registration Number: NCT02301130

Locations: 🇺🇸
The Angeles Clinic, Los Angeles, California, United States
🇺🇸
UCLA Hematology & Oncology Clinic, Los Angeles, California, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

and more 4 locations

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: KHK2823

First Posted Date: 2014-07-04

Last Posted Date: 2024-04-29

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 39

Registration Number: NCT02181699

Locations: 🇬🇧
University of Sussex, Royal Sussex County Hospital, Brighton, United Kingdom
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧
St James's Institute of Oncology, Leeds, United Kingdom

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy